Kerns W D, Arena E, Macia R A, Bugelski P J, Matthews W D, Morgan D G
Department of Experimental Pathology, Smith Kline & French Laboratories, King of Prussia, Pennsylvania 19406.
Toxicol Pathol. 1989;17(1 Pt 2):203-13. doi: 10.1177/019262338901700116.
Fenoldopam mesylate (FM), a selective post-junctional dopaminergic (DA1) vasodilator, causes lesions of large caliber splanchnic arteries (100-800 microns) in the rat characterized by necrosis of medial smooth muscle cells and hemorrhage. FM does not induce lesions in other vascular beds of the rat, or in dogs or monkeys. Dopamine, like FM, causes hemorrhagic lesions of large caliber splanchnic arteries in the rat, as well as fibrinoid necrosis of small caliber arteries (less than 100 microns) of the splanchnic, cerebral, coronary and renal vascular beds. Dopamine is an alpha- and beta-adrenoceptor and a dopaminergic receptor agonist. Because these arterial lesions are thought to result from the pharmacologic activity of these 2 compounds, we sought to ascertain the presence of DA1 receptors in mesenteric arteries of the rat and to determine the role of these or other vascular receptor subtypes in lesion induction. We also studied the process of repair after arterial injury caused by FM or dopamine. The presence of DA1 receptors was confirmed in isolated perfused mesenteric arteries by standard pharmacologic techniques; stimulation by FM resulted in vasodilation which was inhibited by the DA1 receptor antagonist SK&F 83566-C. Likewise, SK&F 83566-C prevented the induction of hemorrhagic lesions of large caliber arteries in rats upon infusion of FM or dopamine. In rats co-exposed to the alpha-adrenoreceptor antagonist phenoxybenzamine (PBZ) and either FM or dopamine, the incidence and severity of hemorrhagic lesions of large caliber arteries were increased, but PBZ prevented the formation of dopamine-induced fibrinoid lesions in arteries of small caliber. Rats exposed concurrently to dopamine, phenoxybenzamine, and SK&F 83566-C were free of all arterial lesions. Thus, the induction of splanchnic arterial lesions in the rat by dopamine and FM is caused by stimulation of, and interaction between, alpha-adrenoceptors and dopaminergic DA1 receptors. Fibrinoid lesions of small arteries (alpha-adrenoceptor-mediated) were repaired, as observed morphologically by 14 d after exposure to dopamine. Hemorrhagic lesions of large caliber arteries (DA1 receptor-mediated) had undergone significant repair by 28 d after exposure to FM but these arteries possessed a thicker media surrounded by adventitial fibrosis. Thus, morphologically distinct receptor-mediated splanchnic arterial lesions induced by dopaminergic and alpha-adrenoceptor agonists follow a markedly different course of repair. Arterial lesions induced by FM or dopamine by activation of post-junctional dopaminergic DA1 receptors may represent a model of polyarteritis nodosa.
甲磺酸非诺多泮(FM)是一种选择性的节后多巴胺能(DA1)血管扩张剂,可导致大鼠大口径内脏动脉(100 - 800微米)出现病变,其特征为中膜平滑肌细胞坏死和出血。FM不会在大鼠的其他血管床、狗或猴子身上诱发病变。多巴胺与FM一样,会导致大鼠大口径内脏动脉出现出血性病变,以及内脏、脑、冠状动脉和肾血管床的小口径动脉(小于100微米)出现纤维蛋白样坏死。多巴胺是一种α和β肾上腺素能受体以及多巴胺能受体激动剂。由于这些动脉病变被认为是这两种化合物的药理活性所致,我们试图确定大鼠肠系膜动脉中DA1受体的存在,并确定这些或其他血管受体亚型在病变诱发中的作用。我们还研究了由FM或多巴胺引起的动脉损伤后的修复过程。通过标准药理技术在离体灌注的肠系膜动脉中证实了DA1受体的存在;FM刺激导致血管舒张,这被DA1受体拮抗剂SK&F 83566 - C抑制。同样,SK&F 83566 - C可防止在输注FM或多巴胺时大鼠大口径动脉出现出血性病变。在同时暴露于α肾上腺素能受体拮抗剂酚苄明(PBZ)和FM或多巴胺的大鼠中,大口径动脉出血性病变的发生率和严重程度增加,但PBZ可防止小口径动脉中多巴胺诱导的纤维蛋白样病变的形成。同时暴露于多巴胺、酚苄明和SK&F 83566 - C的大鼠没有出现所有动脉病变。因此,多巴胺和FM在大鼠中诱发内脏动脉病变是由α肾上腺素能受体和多巴胺能DA1受体的刺激以及它们之间的相互作用引起的。小动脉的纤维蛋白样病变(α肾上腺素能受体介导)在暴露于多巴胺后14天通过形态学观察得以修复。大口径动脉的出血性病变(DA1受体介导)在暴露于FM后28天已进行了显著修复,但这些动脉的中膜更厚,周围有外膜纤维化。因此,由多巴胺能和α肾上腺素能受体激动剂诱导的形态学上不同的受体介导的内脏动脉病变遵循明显不同的修复过程。由FM或多巴胺通过激活节后多巴胺能DA1受体诱导的动脉病变可能代表结节性多动脉炎的一种模型。